TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30582156
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) treatment
Study: 26952547
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg) plus oral prednisolone
Study: 23656601
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (ET) - jaw movement exercise (JME)
Study: 23656601
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (ET) - jaw movement exercise (JME) and psychological intervention (PI)
Study: 23656601
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - pharmacological treatment only
Study: 18355411
Drug: Korean pine
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean pine nut FFA (3 g)
Study: 18355411
Drug: Korean pine
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean pine nut TG (3 g)
Study: 15735101
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (26.6 +/- 4.5 g protein/d containing 44.4 +/- 7.5 mg isoflavones/d)
Study: 15735101
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein (26.6 +/- 4.5 g protein/d)
Study: 3688595
Drug: Super-Char (57.76%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super-Char (57.76% reduction in aspirin absorption)
Study: 3688595
Drug: Actidose-Aqua (50.42%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actidose-Aqua (50.42% reduction in aspirin absorption)
Study: 31408152
Drug: Patient compliance
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient compliance with drug use
Study: 26228536
Drug: Acceptance-Based Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-Based Behavior Therapy (ABBT)
Study: 22019148
Drug: Sham injections
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injections (dilute blood)
Study: 18631346
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with grass pollen extract
Study: 11910260
Drug: Imipramine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine maintenance treatment
Study: 8529326
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg oral dose
Study: 8529326
Drug: Phenytoin 300
Normalized name: phenytoin 300 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 300 mg oral dose
Study: 274992
Drug: BCG administered
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG administered by the multiple-puncture technique
Study: 8912488
Drug: Anticonvulsive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsive treatment with carbamazepine
Study: 30106963
Drug: Dexmedetomidine supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine supplemented morphine analgesia
Study: 29444530
Drug: Morphine analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine analgesia
Study: 22526864
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol and transdermal tulobuterol patch
Study: 20500876
Drug: 7.2% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2% hypertonic saline with 6% poly (O‐2‐hydroxyethyl) starch solution (HH)
Study: 20500876
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid therapy (Ringer's Acetate and saline 9 mg/ml) (control)
Study: 16339664
Drug: ICL670, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICL670, a once-daily oral iron chelator
Study: 9165691
Drug: Intravenous proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous proton pump inhibitors (80 mg pantoprazole or omeprazole bolus followed by 8 mg/hour continuous infusion)
Study: 1642186
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 to 40 mg/day)
Study: 23672109
Drug: Intravenous Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Paracetamol 1g diluted to 20 mls with normal saline
Study: 23672109
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline 20 mls
Study: 19582757
Drug: General occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: General occupational therapy (Control)
Study: 10408031
Drug: Simvastatin (S)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (S) 40 mg daily
Study: 3555578
Drug: Guanfacine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (2 mg once daily)
Study: 25399229
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m(2))
Study: 15747272
Drug: Rofecoxib, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib, 50 mg, 1 hour before surgery
Study: 10371471
Drug: Intravenous gentamicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gentamicin, 5 mg/kg over 60 min, max dose 500 mg (Group I)
Study: 6664154
Drug: Tilidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine (100 mg)
Study: 6852098
Drug: Tilidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine (100 mg); Naloxone (32 mg)
Study: 31703120
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1 g/d)
Study: 27844124
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment program
Study: 19437058
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil (30 mL daily)
Study: 14872552
Drug: Lescol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lescol IR 40 mg twice a day for 7 days
Study: 14872552
Drug: Lescol XL
Normalized name: Lescol XL
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lescol XL 80 mg and 160 mg
Study: 9839524
Drug: Soymilk-supplemented diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soymilk-supplemented diet (400 mL daily, containing about 109 mg of isoflavones)
Study: 2398199
Drug: 0.5% POL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% POL (subgroup treatment for TM)
Study: 22237162
Drug: APF gel
Normalized name: APF Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: APF gel (1.23% F) application for 1 min
Study: 21569378
Drug: Atomoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine treatment for ADHD
Study: 11598848
Drug: 11-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-valent pneumococcal conjugate vaccine with aluminum adjuvant
Study: 11598848
Drug: 11-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-valent pneumococcal conjugate vaccine without aluminum adjuvant
Study: 8079927
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg twice daily for 30 days)
Study: 2647007
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg enprofylline twice daily
Study: 17206696
Drug: Lactobacillus johnsonii,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus johnsonii, LA1 (1010 CFU daily for 12 weeks)
Study: 8310560
Drug: Combined radiation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiation, drug and estrogen treatments (II)
Study: 8310560
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment alone (I)
Study: 8310560
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy alone (III)
Study: 2426899
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 0.030 mg ethinylestradiol (EE) plus 0.150 mg levonorgestrel
Study: 2426899
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 0.150 mg levonorgestrel
Study: 31495419
Drug: Equine-assisted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equine-assisted therapy
Study: 17912998
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral-B 35-MTB)
Study: 10461824
Drug: Thalidomide 100
Normalized name: thalidomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 100 mg
Study: 12001058
Drug: Thalidomide 150
Normalized name: thalidomide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 150 mg
Study: 22133776
Drug: Thalidomide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (all doses)
Study: 386390
Drug: Viloxazine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine (300 mg/d)
Study: 31923017
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 2% lidocaine with 1:100,000 adrenaline
Study: 31923017
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of saline solution (control group)
Study: 31437010
Drug: High-dose D.
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose D. farinae Drops
Study: 31437010
Drug: Medium-dose D.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose D. farinae Drops
Study: 19197266
Drug: sibutramine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sibutramine plus lifestyle modification (combined therapy)
Study: 15599313
Drug: basiliximab +
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: basiliximab + steroids
Study: 19779855
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Control)
Study: 27842543
Drug: Integrated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated care centers providing core HIV services (HIV counseling and testing, education, condom distribution, needle exchange, opioid therapy, STI management, TB screening, ART)
Study: 6997513
Drug: BCG treatment
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG treatment
Study: 20618313
Drug: Magnesium Administration
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium Administration Rank (MAR)
Study: 9250111
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 1200 mg Ca/d
Study: 9250111
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 1300 mg Ca/d
Study: 3234410
Drug: Lidocaine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (100 mg bolus followed by 2 mg min‐1 infusion)
Study: 3234410
Drug: Propafenone (105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (105 mg bolus followed by 300 mg orally every 8 h)
Study: 27026482
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (one dose)
Study: 17038453
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice daily for 10 days followed by placebo (placebo group)
Study: 17038453
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice daily for 10 days followed by continued doxycycline 100 mg twice daily over 4 months (doxycycline group)
Study: 11071595
Drug: Energy-enriched formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-enriched formula (1.5 kcal/mL)
Study: 8923869
Drug: Two 200‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 200‐mg testosterone pellets (400 mg, 3 mg/day)
Study: 8923869
Drug: Four 200‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 200‐mg testosterone pellets (800 mg, 6 mg/day)
Study: 8923869
Drug: Four 200‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 200‐mg testosterone pellets (800 mg, 6 mg/day) plus a single im injection of 300 mg depot medroxyprogesterone acetate (DMPA)
Study: 4018502
Drug: Morphine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (100 micrograms/kg body wt as a bolus intravenously)
Study: 27237200
Drug: SRP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP and PDT (1% methylene blue solution)
Study: 25121804
Drug: Acetaminophen ER
Normalized name: acetaminophen Extended Release Oral Tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen ER 1300 mg three times daily
Study: 22382344
Drug: Certolizumab and
Normalized name: CERTOLIZUMAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certolizumab and golimumab (anti-TNF treatment)
Study: 22382344
Drug: DMARD (nonbiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD (nonbiological disease-modifying antirheumatic drug)
Study: 12890127
Drug: Sumatriptan 50
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 50 mg plus metoclopramide 10 mg
Study: 12890127
Drug: Sumatriptan 50
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 50 mg plus placebo
Study: 1546723
Drug: 60-minute infusion/glycopyrrolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-minute infusion/glycopyrrolate pretreatment
Study: 19646081
Drug: Talipexole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Talipexole hydrochloride tablets alone
Study: 19646081
Drug: Talipexole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Talipexole hydrochloride tablets with Madopar (co-beneldopa)
Study: 17462549
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (100 mg intramuscularly for 3 months)
Study: 17462549
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (optimally conventional treatment of CKD)
Study: 14718433
Drug: Intranasal Moli1901
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Moli1901
Study: 12563960
Drug: Cefuroxime (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (250 mg orally twice daily)
Study: 6376951
Drug: Crystalline amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalline amino acid‐glucose (CAA‐G) diet
Study: 6376951
Drug: Partially hydrolyzed
Normalized name: Human Skin Proteins, Partially Hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolyzed protein‐glucose (PHP‐G) diet
Study: 31251694
Drug: Interval cytoreductive
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 20858539
Drug: Acitretin loaded
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin loaded Nanostructured Lipid Carriers (ActNLCs) gel
Study: 20858539
Drug: Act plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Act plain gel
Study: 1501354
Drug: PAR3 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAR3 group (3 mL of MVI‐Pediatric supplement, parenterally fed)
Study: 1501354
Drug: PAR2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAR2 group (2 mL, parenterally fed)
Study: 29111980
Drug: Metformin continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin continued group
Study: 29111980
Drug: Metformin discontinued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin discontinued group
Study: 25877422
Drug: Auto-crosslinked hyaluronic
Normalized name: hyaluronic acid, crosslinked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto-crosslinked hyaluronic acid gel (3 ml)
Study: 25877422
Drug: Auto-crosslinked hyaluronic
Normalized name: hyaluronic acid, crosslinked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto-crosslinked hyaluronic acid gel
Study: 21273897
Drug: Vibration treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration treatment
Study: 11925463
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with 80 mg of zinc as zinc oxide plus 2 mg of copper as cupric oxide
Study: 3540871
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium 550 mg
Study: 9620100
Drug: acetaminophen 325
Normalized name: acetaminophen 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 325 mg
Study: 9620100
Drug: bromfenac 25
Normalized name: bromfenac 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromfenac 25 mg (fed)
Study: 9620100
Drug: bromfenac 25
Normalized name: bromfenac 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromfenac 25 mg (fasted)
Study: 2615927
Drug: Clomipramine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine, 10 mg i.v.
Study: 2615927
Drug: Desipramine, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine, 25 mg i.m.
Study: 1687425
Drug: metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100 mg
Study: 28145158
Drug: Sitagliptin (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (acute dosing)
Study: 21696807
Drug: Doxazosin gastrointestinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin gastrointestinal therapeutic system (doxazosin-GITS) 4 mg
Study: 10801250
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg
Study: 19465881
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 to 20 mg/day
Study: 10952418
Drug: Nonselective endothelin-1
Normalized name: nitric oxide synthase endothelial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective endothelin-1 inhibitors
Study: 10952418
Drug: Selective endothelin
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective endothelin A receptor inhibitors
Study: 10952418
Drug: Nonselective antagonism
Normalized name: ganirelix acetate Prefilled Syringe [Antagon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective antagonism of endothelin receptors
Study: 24924874
Drug: Increased awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased awareness and acceptance of emotions and thoughts during treatment
Study: 12588577
Drug: HCTZ 25
Normalized name: HCTZ 25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 25 mg
Study: 2257857
Drug: Cicletanine 50
Normalized name: cicletanine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 50 mg
Study: 3867354
Drug: Cicletanine 150
Normalized name: cicletanine
DrugBank: Cicletanine (DB12766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 150 mg
Study: 20578209
Drug: sotrastaurin 100
Normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotrastaurin 100 mg
Study: 20578209
Drug: cyclosporine 400
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporine 400 mg
Study: 20578209
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sotrastaurin with 400 mg cyclosporine
Study: 20578209
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sotrastaurin with 100 mg cyclosporine
Study: 7767427
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline followed by albuterol (PA group; n = 25)
Study: 7767427
Drug: Intramuscular epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular epinephrine
Study: 7028411
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg, intramuscular injection, three times daily for 7-10 days
Study: 7028411
Drug: Ampicillin 500
Normalized name: ampicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 500 mg, intramuscular injection, three times daily for 7-10 days
Study: 25216508
Drug: Spinal cord
Normalized name: BOS TAURUS SPINAL CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal cord stimulation (SCS) in combination with best medical treatment (BMT)
Study: 22893497
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment (BMT) only
Study: 20120423
Drug: Dapsone gel
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone gel 5% combined with adapalene gel 0.1%
Study: 20120423
Drug: Dapsone gel
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone gel 5% combined with benzoyl peroxide gel 4%
Study: 20120423
Drug: Dapsone gel
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone gel 5% combined with moisturizer
Study: 8909483
Drug: Two-dose mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose mixed regimen (M at 2 months and T at 4 months)
Study: 8909483
Drug: Two-dose mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose mixed regimen (MT-)
Study: 6405772
Drug: Codeine 60
Normalized name: codeine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 60 mg by mouth
Study: 16167458
Drug: Antipsychotic polypharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic polypharmacy (APP)